INDEPENDENT HEOR SUPPORT

Clinical Evidence &
Economic Modelling
for Canadian HTA Submissions

Hi, I’m Mohammed, an independent, early-career HEOR consultant. I support emerging biotech teams with focused clinical evidence work and health economic modelling for submissions to Canada’s Drug Agency (CDA-AMC, formerly CADTH).

Evidence synthesisDecision modellingHealth technology assessment (HTA)
01 / SERVICES

How I support your team.

01

Clinical evidence synthesis

Structured reviews of clinical studies, with critical appraisal, certainty of evidence assessment, and attention to comparators relevant to Canadian practice.

02

Economic modelling and analysis

Focused cost-utility modelling in R, with deterministic and probabilistic sensitivity analyses and price-threshold analysis. We would confirm the required model format before agreeing on submission work.

03

HTA submission support

Defined clinical or economic evidence summaries that your team can use when preparing a Canadian reimbursement submission.

02 / PROJECT FIT

What are you trying
to figure out?

Choose the closest need. This is a starting point for a scoped conversation, not a promise that every project is the right fit.

SELECT A PROJECT NEED

ONE POSSIBLE DELIVERABLE01 / 04

Focused evidence map

A structured scan of published clinical and economic evidence, with a concise table of study characteristics, relevant outcomes, and visible gaps.

Useful inputs

Population, intervention, comparator, outcomes, and the decision you need to inform.

Final scope, methods, and timing would be agreed together before work begins.

03 / BACKGROUND

Hi, I’m Mohammed.

I completed an MPH at the University of Ottawa, with a focus on health economics and policy, after a BSc in biomedical sciences at Brock University.

My experience in HTA includes clinical evidence assessment and health economic evaluation of health technologies, including decision modelling. Combined with my health policy training, it has given me a strong grounding in Canada’s reimbursement and market access pathways.